Protein typing of circulating microvesicles allows real-time monitoring of glioblastoma therapy

Nature Medicine

Volumn 18, Issue 12, 2012, Pages 1835-1840

  Shao, Huilin ^a,b   Chung, Jaehoon ^a   Balaj, Leonora ^a   Charest, Alain ^c   Bigner, Darell D ^d   Carter, Bob S ^e   Hochberg, Fred H ^a   Breakefield, Xandra O ^a,b   Weissleder, Ralph ^a,b   Lee, Hakho ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DUKE UNIVERSITY MEDICAL CENTER   (United States)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GELDANAMYCIN; PROTEIN; TEMOZOLOMIDE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD SAMPLING; CANCER DIAGNOSIS; CELL VACUOLE; CONTROLLED STUDY; DRUG EFFICACY; GLIOBLASTOMA; HUMAN; HUMAN CELL; MICROFLUIDICS; MICROVESICLE; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE; PRIORITY JOURNAL; TUMOR XENOGRAFT;

CELL LINE, TUMOR; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETITE NANOPARTICLES; MICROFLUIDIC ANALYTICAL TECHNIQUES; TRANSPORT VESICLES; TUMOR MARKERS, BIOLOGICAL;

EID: 84870931536     PISSN: 10788956     EISSN: 1546170X     Source Type: Journal    
DOI: 10.1038/nm.2994     Document Type: Article

References (38)

1. Maheswaran, S. et al. Detection of mutations in EGFR in circulating lung-cancer cells. N. Engl. J. Med. 359, 366-377 (2008).
2. Kulasingam, V., Pavlou, M.P. & Diamandis, E.P. Integrating high-throughput technologies in the quest for effective biomarkers for ovarian cancer. Nat. Rev. Cancer 10, 371-378 (2010).
3. Simpson, R.J., Lim, J.W., Moritz, R.L. & Mathivanan, S. Exosomes: proteomic insights and diagnostic potential. Expert Rev. Proteomics 6, 267-283 (2009).
4. Théry, C., Ostrowski, M. & Segura, E. Membrane vesicles as conveyors of immune responses. Nat. Rev. Immunol. 9, 581-593 (2009).
5. Skog, J. et al. Glioblastoma microvesicles transport RNA and proteins that promote tumour growth and provide diagnostic biomarkers. Nat. Cell Biol. 10, 1470-1476 (2008).
6. Al-Nedawi, K. et al. Intercellular transfer of the oncogenic receptor EGFRvIII by microvesicles derived from tumour cells. Nat. Cell Biol. 10, 619-624 (2008).
7. Simons, M. & Raposo, G. Exosomes - vesicular carriers for intercellular communication. Curr. Opin. Cell Biol. 21, 575-581 (2009).
8. Lee, T.H. et al. Microvesicles as mediators of intercellular communication in cancer - the emerging science of cellular 'debris'. Semin. Immunopathol. 33, 455-467 (2011).
9. Cocucci, E., Racchetti, G. & Meldolesi, J. Shedding microvesicles: artefacts no more. Trends Cell Biol. 19, 43-51 (2009).
10. Graner, M.W. et al. Proteomic and immunologic analyses of brain tumor exosomes. FASEB J. 23, 1541-1557 (2009).
11. Sanderson, M.P. et al. Generation of novel, secreted epidermal growth factor receptor (EGFR/ErbB1) isoforms via metalloprotease-dependent ectodomain shedding and exosome secretion. J. Cell. Biochem. 103, 1783-1797 (2008).
12. Balaj, L. et al. Tumour microvesicles contain retrotransposon elements and amplified oncogene sequences. Nat. Commun. 2, 180 (2011).
13. Lee, H., Sun, E., Ham, D. & Weissleder, R. Chip-NMR biosensor for detection and molecular analysis of cells. Nat. Med. 14, 869-874 (2008).
14. Issadore, D. et al. Miniature magnetic resonance system for point-of-care diagnostics. Lab Chip 11, 2282-2287 (2011).
15. Haun, J.B. et al. Micro-NMR for rapid molecular analysis of human tumor samples. Sci. Transl. Med. 3, 71ra16 (2011).
16. Théry, C., Zitvogel, L. & Amigorena, S. Exosomes: composition, biogenesis and function. Nat. Rev. Immunol. 2, 569-579 (2002).
17. Haun, J.B., Devaraj, N.K., Hilderbrand, S.A., Lee, H. & Weissleder, R. Bioorthogonal chemistry amplifies nanoparticle binding and enhances the sensitivity of cell detection. Nat. Nanotechnol. 5, 660-665 (2010).
18. Thery, C., Amigorena, S., Raposo, G. & Clayton, A. Isolation and characterization of exosomes from cell culture supernatants and biological fluids. Curr. Protoc. Cell Biol. 30, 3.22 (2006).
19. Fleming, T.P. et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors. Cancer Res. 52, 4550-4553 (1992).
20. Mishima, K. et al. Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression. Acta Neuropathol. 111, 483-488 (2006).
21. Wykosky, J., Gibo, D.M., Stanton, C. & Debinski, W. EphA2 as a novel molecular marker and target in glioblastoma multiforme. Mol. Cancer Res. 3, 541-551 (2005).
22. Parsons, D.W. et al. An integrated genomic analysis of human glioblastoma multiforme. Science 321, 1807-1812 (2008).
23. Dang, L. et al. Cancer-associated IDH1 mutations produce 2-hydroxyglutarate. Nature 462, 739-744 (2009).
24. Italiano, J.E.J., Mairuhu, A.T. & Flaumenhaft, R. Clinical relevance of microparticles from platelets and megakaryocytes. Curr. Opin. Hematol. 17, 578-584 (2010).
25. Pedersen, N.M. et al. Expression of epidermal growth factor receptor or ErbB3 facilitates geldanamycin-induced down-regulation of ErbB2. Mol. Cancer Res. 7, 275-284 (2009).
26. Trepel, J., Mollapour, M., Giaccone, G. & Neckers, L. Targeting the dynamic HSP90 complex in cancer. Nat. Rev. Cancer 10, 537-549 (2010).
27. Zhu, H. et al. The novel Hsp90 inhibitor NXD30001 induces tumor regression in a genetically engineered mouse model of glioblastoma multiforme. Mol. Cancer Ther. 9, 2618-2626 (2010).
28. Zhu, H. et al. Oncogenic EGFR signaling cooperates with loss of tumor suppressor gene functions in gliomagenesis. Proc. Natl. Acad. Sci. USA 106, 2712-2716 (2009).
29. Cancer Genome Atlas Research Network. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 455, 1061-1068 (2008).
30. Verhaak, R.G. et al. Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17, 98-110 (2010).
31. Pedersen, M.W., Meltorn, M., Damstrup, L. & Poulsen, H.S. The type III epidermal growth factor receptor mutation. Biological significance and potential target for anti-cancer therapy. Ann. Oncol. 12, 745-760 (2001).
32. Mellinghoff, I.K. et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 353, 2012-2024 (2005).
33. Galbán, C.J. et al. The parametric response map is an imaging biomarker for early cancer treatment outcome. Nat. Med. 15, 572-576 (2009).
34. Galbán, C.J. et al. Prospective analysis of parametric MRI biomarkers: Identification of early and distinct glioma response patterns not predicted by standard radiographic assessment. Clin. Cancer Res. 17, 4751-4760 (2011).
35. Tsien, C. et al. Parametric response map as an imaging biomarker to distinguish progression from pseudoprogression in high-grade glioma. J. Clin. Oncol. 28, 2293-2299 (2010).
36. Elkhaled, A. et al. Magnetic resonance of 2-hydroxyglutarate in IDH1-Mutated low-grade gliomas. Sci. Transl. Med. 4, 116ra5 (2012).
37. Wei, L.H. et al. Changes in tumor metabolism as readout for mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clin. Cancer Res. 14, 3416-3426 (2008).
38. Yoon, T.J., Lee, H., Shao, H. & Weissleder, R. Highly magnetic core-shell nanoparticles with a unique magnetization mechanism. Angew. Chem. Int. Edn Engl. 50, 4663-4666 (2011).